


# CIG Pannonia

Recommendation: Under revision

Target price (e-o-y): Under revision

Share price as of 27/02/2023	HUF 342
Number of diluted shares [million]	94.4
Market capitalization [HUF bn/EUR mn]	32.3 / 82.6
Daily turnover 12M [HUF million]	5.1
Bloomberg	PANNONIA HB
Reuters	CIGP.BU
Free float	41.3%
52-week range	HUF 250–342



## CIG Pannonia reported solid results for '23

### Equity Analyst

Gabor Bukta  
+361 489 2272  
g.bukta@con.hu


55-61 Alkotás  
Street,  
Budapest  
www.con.hu

- CIG Pannonia (Pannonia) reported a PAT of HUF 1.51bn for Q4/23 compared to HUF 0.95bn in Q4/22 (+59% YoY) and HUF 0.77bn in Q3/23 (+96% QoQ). Other comprehensive income including the changes in the fair value of other financial assets (OPUS shares and government securities) valued at fair value was HUF 1.77bn compared to HUF 1.17bn in Q4/22. Total comprehensive income came in at HUF 2.2bn in Q4/23, up from HUF 1.75bn in Q4/22.
- Pannonia's full-year after-tax profit came in at HUF 2.87bn in 2023 (EPS of HUF 30.6), up by 87% from HUF 1.54bn (EPS of HUF 16.3) in 2022. As a result of using IFRS 17 accounting transition methodology increased Pannonia's after-tax result for 2022 from HUF 1.41bn (as reported in the Q3/23 flash reports) to HUF 1.54bn, while its consolidated equity increased by HUF 7.3bn (+56%). However, due to the tax impact of this transition a non-recurring corporate tax liability incurred in an amount of HUF 0.5bn. Also importantly, according to Pannonia's best estimate, the extra profit tax of HUF 0.69bn was recorded in 2023 as against HUF 0.6bn in 2022. Adjusting for these tax charges of HUF 1.19bn in total for 2023 and HUF 0.6bn for 2022, consolidated after tax profit increased by 90% YoY from HUF 2.13bn to HUF 4.06bn in 2023, implying an adjusted EPS of HUF 43.2 compared to HUF 22.7 in 2022.
- Unconsolidated life insurance after tax profit was HUF 2.94bn (+38% YoY), while non-life unconsolidated after profit came in at HUF 0.78bn compared to a loss of HUF 0.44bn in 2022.
- Pannonia's technical result, including the impact of the surtax, also increased significantly by HUF 0.63bn or 66% YoY, with the non-life segment's technical results improving by HUF 0.47bn on an annual basis.
- The primary reasons for the outstanding earnings growth were (i) the growth of the insurance portfolio, (ii) a great improvement in profitability due to economies of scale and efficiency containment measures, and (iii) and a higher yield environment. The latter itself contributed by HUF 1.1bn or 38% to total after-tax profit in 2023. Premium

income surpassed HUF 10bn in every quarter of 2023, reaching HUF 43bn compared to HUF 31.85bn (+35% YoY), mainly driven by credit coverage insurances, corporate property insurances and single premium unit-linked life insurances. As for the segment breakdown, life Insurance premiums rose by 16% YoY, while non-life premiums grew by 142%.

- Pannonia’s capital position has constantly been stable, with total shareholder's equity of HUF 23.26bn (up by 14% YoY) at the end of 2023. The capital adequacy ratio stood at 240% at the end of December 2023 compared to 215% at the end of September, 2023, significantly above the required rate by the supervisors of 150%.

Breakdown of the YoY increase of the IFRS 17 consolidated after tax result (HUF mn)



Source: Pannonia

Outlook

- Based on the strong increase in premium income achieved in 2023, we need to revisit our net income forecasts for the next years. Despite the unfavorable regulatory and economic environment, Pannonia has a solid growth potential and stable capital situation. **Due to the transfer of coverage, we withdrew our earnings forecasts in November and we put our e-o-y TP under revision until further earnings revision.**
- Our previous TP was set at HUF 410 a share and the recommendation was BUY on CIG Pannonia. We remain confident that Pannonia's resilient and flexible organization can weather the impending economic uncertainties, rather than being overwhelmed by it, while remaining committed to market expansion in both organic and inorganic ways and to product innovation.

## Disclaimer

Concorde Securities Ltd. does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interests that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For analysts' certification and other important disclosures, please refer to the "Disclaimer" section at the end of this report.

### DISCLAIMER I.

This research report has been prepared by Concorde Securities Ltd., a full-service Hungarian investment banking, investment management and brokerage firm. Concorde Securities Ltd. is under the supervision of the National Bank of Hungary in its capacity as financial supervisory authority.

Concorde Securities Ltd. is registered in Hungary and does not have any subsidiaries, branches or offices outside of Hungary. Therefore we are not allowed to provide direct investment banking services to US investors and restrictions may apply to our potential investment banking services according to your country's jurisdiction.

Our salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are their own and may be contrary to the opinions expressed in our research products, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed by our analysts or traders.

Our research, sales and trading professionals are paid based on the profitability of the respective divisions of Concorde Securities Ltd., which from time-to-time may include revenues from the firm's capital market activity. Concorde Securities Ltd. does not prohibit analysts, salespeople and traders from maintaining a financial interest in the securities or futures of any companies that they cover or trade on their clients' behalf in strict compliance with the Hungarian Capital Markets Act.

### ANALYSTS CERTIFICATION

The research analysts undersigned and responsible for the preparation of this report hereby certify that (i) the views expressed in this research report accurately reflect their personal views about any and all of the securities or issuers referred to in this research report; (ii) no part of the analysts' compensation was, is or will be directly or indirectly related to the specific recommendation or views expressed in this report and (iii) no part of their compensation is tied to any specific investment transactions performed by Concorde Securities Ltd.

Name and job title of individuals involved in the production of this report are disclosed at the end of this report.

Concorde Securities Ltd. is a leading manager and underwriter of Hungarian equity offerings. We have investment banking and other business relations with a substantial percentage of the companies traded on the Budapest Stock Exchange and covered by our research department. Concorde Securities Ltd, its directors and employees may have a position in these securities, which may change at any time.

Concorde Securities Ltd. acted as Lead Manager of the private and public share placement of the shares of FHB in 2003, Masterplast in 2012 and Duna House in 2016. Concorde Securities Ltd. acted as the Co-lead Manager of Gedeon Richter's exchangeable bond issue in September 2004. Concorde Securities Ltd. has provided financial advice to Magyar Telekom.

### EXPLANATION OF RATINGS AND METHODOLOGY

Rating	Trigger
Buy	Total return is expected to exceed 20% in the next 12 months
Accumulate	Total return is expected to be in the range of 10-20%
Neutral	Total return is expected to be in the range of 10%-(-10%)
Reduce	Total return is expected to be in the range of -10-(-20%)
Sell	Total return is expected to be lower than -20%
Under Revision	The stock is put Under Revision if the covering analyst considers new information may change the valuation materially and if this may take more time.
Coverage in transition	Coverage in transition rating is assigned to a stock if there is a change in analyst.

### Securities prices:

Prices are taken as of the previous day's close on the home market unless otherwise stated.

### Valuations and risks:

Analysis of specific risks to set stock target prices highlighted in our investment case(s) are outlined throughout the report. For details of methodologies used to determine our price targets and risks related to the achievement of the targets referred to in the main body of the report or at [Rating Methodology](#) on our website, visit ([https://www.con.hu/wp-content/uploads/2016/04/Methodology\\_concorde\\_research.pdf?tstamp=201710021038](https://www.con.hu/wp-content/uploads/2016/04/Methodology_concorde_research.pdf?tstamp=201710021038))

### Research disclosures:

Concorde Securities Ltd. may have published other investment recommendations in respect of the same securities/instruments recommended in this report during the preceding 12 months. Disclosure of previous investment recommendations produced by Concorde Securities Ltd. in the previous 12 months can be found at [Rating history](#). (<https://www.con.hu/wp-content/uploads/2016/04/Rating-history.pdf?tstamp=201710021038>)

#### *GENERAL*

This report is provided for information purposes only and does not represent an offer for sale, or the solicitation of any offer to buy or sell any securities.

The information, and any opinions, estimates and forecast have been obtained from sources believed by us to be reliable, but no representation or warranty, express or implied is made by us as to their accuracy or completeness. The information, opinions, estimates and forecasts may well be affected by subsequent changes in market conditions. This document may not be reproduced in whole or in part, or published for any purpose.

REPRODUCTION OR REBROADCAST OF ANY PORTION OF THIS RESEARCH REPORT IS STRICTLY PROHIBITED WITHOUT THE WRITTEN PERMISSION OF CONCORDE SECURITIES LTD.

### DISCLAIMER II.

This research/commentary was prepared by the assignment of Budapest Stock Exchange Ltd. (registered seat: 1054 Budapest, Szabadság tér 7. Platina torony I. ép. IV. emelet; company registration number: 01-10-044764, hereinafter: BSE) under the agreement which was concluded by and between BSE and Concorde Securities Ltd. (registered seat: H-1123 Budapest Alkotás utca 50., company registration number: 01-10-043521, hereinafter: Investment Service Provider)

BSE shall not be liable for the content of this research/commentary, especially for the accuracy and completeness of the information therein and for the forecasts and conclusions; the Service Provider shall be solely liable for these. The Service Provider is entitled to all copyrights regarding this research/commentary however BSE is entitled to use and advertise/spread it but BSE shall not modify its content.

This research/commentary shall not be qualified as investment advice specified in Point 9 Section 4 (2) of Act No. CXXXVIII of 2007 on Investment Firms and Commodity Dealers and on the Regulations Governing their Activities. Furthermore, this document shall not be qualified as an offer or call to tenders for the purchase, sale or hold of the financial instrument(s) concerned by the research/commentary.